Skip to content
Home
  • Contact Us
  • About
    • Our Company
    • Executive Team
    • Board of Directors
    • Scientific Founders
  • Technology
    • Bacteriophage background
    • Phage therapy
    • Biomarker discovery
  • Case Studies
  • Pipeline
  • Investors
  • Newsroom
  • Publications
  • Careers
  • +972-72-3942377
  • info@biomx.com
  • Connect with us on LinkedIn

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Executive Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Forms
  • Stock Data
    • NYSE: PHGE
    • TASE: PHGE
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
May 08, 2025 7:00am EDT

BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025

Apr 01, 2025 6:30am EDT

BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure

Mar 31, 2025 6:30am EDT

BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)

Mar 25, 2025 6:30am EDT

BiomX Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business and Program Updates

Mar 19, 2025 12:35pm EDT

BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

Feb 26, 2025 8:00am EST

BiomX Announces a Series of Financings for Aggregate Gross Proceeds of $12 Million

Dec 16, 2024 8:00am EST

BiomX Inc. Receives Notice of Compliance with NYSE American Continued Listing Standards

Nov 14, 2024 6:30am EST

BiomX Announces Third Quarter 2024 Financial Results and Provides Business and Program Updates

Nov 12, 2024 12:20pm EST

BiomX to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 14, 2024

Oct 15, 2024 7:00am EDT

BiomX Announces a Mandatory Unit Separation

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • …13
  • Next
RSS

Investor Contact Information

Company

BiomX, Inc.
708 Quince Orchard Rd
Suite 205
Gaithersburg, MD 20878
USA
info@biomx.com

Investor Relations

Ben Cohen
benc@biomx.com

  • Email Alerts
  • Contacts
  • RSS News Feed
  • Advancing Medicine
    Precisely.
  • 2022 © All rights reserved to BiomX
    Terms and Conditions | Privacy Policy

  • UX+UI+Development by Omnis

  • About

    • Our Company
    • Executive Team
    • Board of Directors
    • Scientific Founders
  • Technology

    • BACTERIOPHAGE BACKGROUND
    • Phage Therapy
    • Biomarker Discovery
  • Pipeline

    • Cystic Fibrosis
    • Atopic Dermatitis
    • IBD/PSC
    • Colorectal cancer
  • Investors

    • OVERVIEW
    • NEWS & EVENTS
    • COMPANY INFO
    • FINANCIAL INFO
    • STOCK DATA
    • SEC FILINGS
    • GOVERNANCE

We use cookies to analyze traffic and continually improve our site.

More info